Haemonetics Corporation (HAE) shares surged 27.3 percent to $64.58 on Thursday after the medical technology company posted higher quarterly earnings and raised parts of its fiscal 2026 revenue outlook, despite reporting a decline in sales.
While earnings increased to $0.81 per share from $0.66, the second-quarter net income increased by 14.3 percent to $38.68 million from $33.83 million in the previous year. Revenue dropped 5.3 percent to $327.32 million, with plasma revenue down 9.5 percent, hospital revenue down 5.1 percent, and blood center revenue down 17.6 percent. Nevertheless, sales were higher than the Street's projected $311.49 million.
In contrast to the previous close of $50.72 on the New York Stock Exchange, the stock opened at $56.88 and fluctuated between $56.85 and $65.73 before closing at $64.58. With 2.37 million shares traded, the volume was significantly higher than the average of 1.01 million.
Over the past 52 weeks, the price of Haemonetics' shares has fluctuated between $47.32 and $94.99.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.